Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
NCT04968548 · View on ClinicalTrials.gov ↗
Study Summary
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Conditions Studied
Interventions
- PROCEDURE Blood collection
Study Locations (20)
North Carolina
- The University of North Carolina — Chapel Hill
- Duke University — Durham
- Durham VA Health Care System — Durham
- W.G. (Bill) Hefner VA Medical Center — Salisbury
- Novant Health Cancer Research — Winston-Salem
Kentucky
- St. Elizabeth Edgewood Hospital — Edgewood
- Norton Cancer Institute — Louisville
- Owensboro Health — Owensboro
Florida
- Orlando Health, Inc. — Orlando
- Sarasota Memorial Hospital — Sarasota
Missouri
- Harry S. Truman Memorial Veterans' Hospital — Columbia
- Washington University in St. Louis — St Louis
New York
- Northwell Health — New Hyde Park
- University of Rochester — Rochester
California
- Scripps Memorial Hospital — Encinitas
Colorado
- Centura Health — Lakewood
Connecticut
- VA Connecticut Healthcare System — West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2021-09-17 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04968548
The ClinicalTrials.gov registry entry for NCT04968548 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nucleix, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention — of which Blood collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04968548 reports 20 study locations spanning 11 distinct geographic areas — top geographies include North Carolina, Kentucky, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04968548 about?
NCT04968548 is a clinical study titled "Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening". This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
What is the current status of trial NCT04968548?
This trial is currently active not recruiting. The enrollment target is 5,000 participants. The study started on 2021-09-17. Estimated completion is 2025-12.
What conditions does trial NCT04968548 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04968548?
The interventions under investigation include: Blood collection (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04968548?
This trial is sponsored by Nucleix, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04968548 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.